Clinical Trials Sponsored by Eisai Inc.

Total 35741 results

Eisai Inc.
Halozyme Therapeutics

Terminated

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
Yale University
Eisai Inc.

Completed

A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma

Peripheral T-Cell Lymphoma

United States
Eisai Inc.
PPD; Covance

Terminated

A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures

Osteotomy | Carpal Tunnel | Arthroscopy | Bunionectomy
Indiana University
Eisai Inc.

Completed

Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer

Ovarian Cancer

United States
Mayo Clinic
Eisai Inc.

Terminated

Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery

Orthopedic Surgery | Procedural Sedation | Regional Anesthesia Block

United States
Northwell Health
Eisai Inc.

Completed

Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation

Epilepsy | Developmental Disabilities | Mental Retardation

United States
Eisai Limited
Merck Sharp & Dohme LLC

Completed

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

Italy, Korea, Republic of, Poland, United States, Australia, Belgium, Canada, China, France, Germany, Hong Kong, Israel, Japan, Malaysia, Philippines, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
Emory University
Eisai Inc.

Terminated

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States
Duke University
Eisai Inc.

Completed

Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide

Malignant Glioma

United States
Northwestern University
Eisai Inc.

Unknown

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...

United States
Emory University
Eisai Inc.

Terminated

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Breast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, Breast

United States
Vector Oncology
Eisai Inc.

Terminated

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

HER-2 Positive Breast Cancer

United States
Eisai Inc.
PPD; Covance

Completed

Study to Assess Safety and Efficacy of AQUAVAN® Injection for Sedation During Cardiac Catheterization

Angioplasty | Coronary Catheterization
Eisai Limited
Merck Sharp & Dohme LLC

Completed

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Osteosarcoma | Tumors | Differentiated Thyroid Cancer (DTC) | Solid Malignant Tumors

Spain, Italy, United States, United Kingdom, France, Germany
Kurume University
Eisai Inc.; Mebix Inc

Completed

An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Transitioning to Lemborexant in Japanese Subjects With Insomnia

Insomnia

Japan
Duke University
Genentech, Inc.; Eisai Inc.

Terminated

A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme | Malignant Glioma | Gliosarcoma

United States
Duke University
Genentech, Inc.; Eisai Inc.

Terminated

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme | Gliosarcoma

United States
Eisai Co., Ltd.
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Solid Neoplasms

Japan
Eisai Co., Ltd.
Merck Sharp & Dohme LLC

Completed

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Spain, France, Italy, Japan, Russian Federation, United Kingdom
Eisai Co., Ltd.
Ono Pharmaceutical Co. Ltd

Completed

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Japan
Eisai Co., Ltd.
Merck Sharp & Dohme LLC

Completed

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Solid Tumors

Japan
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Neoplasms, Ovarian

Australia, United States, Korea, Republic of, Chile, Belgium, Italy, Spain, Israel, Japan
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Carcinoma, Non-Small-Cell Lung

United States, Australia, Belgium, Chile, France, Spain
Eisai Inc.
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Solid Tumor

United States, Spain, United Kingdom, France
Massachusetts General Hospital
Eisai Inc.

Active, not recruiting

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Angiosarcoma | Epithelioid Hemangioendothelioma

United States
University of Chicago
Eisai Inc.

Terminated

Vaccination Plus Ontak in Patients With Metastatic Melanoma

Melanoma

United States
Eisai Inc.
Purdue Pharma LP

Completed

A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

Insomnia Disorders

Canada
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study of Lemborexant-Alcohol Interaction in Healthy Subjects

Healthy Subjects

Canada
University of Pennsylvania
Eisai Inc.

Completed

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

Obesity

United States
University of Iowa
Eisai Inc.

Terminated

Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme (Temodar)

Primary Glioblastoma Multiforme

United States
University of Utah
Eisai Inc.

Completed

Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia | AML

United States
Changhai Hospital
Eisai China Inc.

Completed

A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis

Chronic Erosive Gastritis

China
Duke University
Eisai Inc.; Cephalon

Completed

Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Kentuckiana Cancer Institute
Eisai Inc.

Unknown

A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma (KARE003)

Glioma

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

Renal Impairment

United States
Eisai Inc.
Purdue Pharma LP

Completed

Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older

Healthy Subjects

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

Healthy Subjects

United States
Eisai Inc.
Helsinn Healthcare SA

Completed

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

Multiple Myeloma

United States
University of Pittsburgh
Eisai Inc.

Withdrawn

Zonisamide for Fibromyalgia & Migraine

Migraine | Fibromyalgia

United States
Kentuckiana Cancer Institute
Eisai Inc.

Unknown

Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma

Newly Diagnosed Supratentorial Malignant Glioma

United States
University of Florida
Eisai Inc.

Recruiting

Fycompa in Catamenial Epilepsy

Catamenial Epilepsy

United States
Italian Sarcoma Group
Eisai Inc.

Recruiting

Eribulin in Advanced Solitary Fibrous Tumor (ERASING)

Solitary Fibrous Tumor

Italy
University of Arizona
Eisai Inc.

Completed

Fycompa Titration Intervals and Effects on Retention Rate

Epilepsy

United States
Stony Brook University
Eisai Inc.

Terminated

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia

Irregular Sleep-Wake Rhythm Disorder

United States, Japan, United Kingdom
Institut Paoli-Calmettes
Eisai Inc.

Withdrawn

Eribulin in Brain Metastases From HER2-negative Breast Cancer (ERIBRAIN)

Metastatic Breast Cancer

France
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

Obstructive Sleep Apnea | Healthy Subjects

United States
University of Cincinnati
Eisai Inc.

Withdrawn

Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme

Glioblastoma Multiforme

United States
Eisai Inc.
Children's Oncology Group

Completed

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (BOLD 113)

Solid Tumors | Pediatrics

United States

3

Subscribe